Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HiFiBiO Therapeutics

Request full access

An emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases

Cambridge, United StatesFounded 2013Biotech & Life Sciences

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, Massachusetts. The company is committed to improving patient lives with single-cell precision. This means they focus on developing treatments that target individual cells, which can be more effective and have fewer side effects than traditional treatments.

HiFiBiO Therapeutics operates in the biotech market, serving clients in the healthcare sector, including hospitals, clinics, and other medical facilities. Their business model revolves around the development and commercialization of innovative biotech solutions, particularly in the field of drug discovery and development.

One of their key innovations is the Drug Intelligence Science (DIS®) platform, a proprietary translational platform that uses artificial intelligence (AI) to enhance the success rate of drug discovery and development. This platform was recognized as the "AI Innovation of the Year" in the 2023 BioTech Breakthrough Awards, highlighting its potential to revolutionize the biotech industry.

Furthermore, HiFiBiO Therapeutics has received approval from the Chinese National Medical Products Administration (NMPA) for their Investigational New Drug (IND) application for HFB200301, an innovative anti-tumor monoclonal antibody. This is a type of drug that can recognize and attack specific cells in the body, in this case, tumor cells.

The company generates revenue through the development and sale of these innovative biotech solutions, as well as through partnerships with other healthcare and biotech companies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
None listed
Dealroom signal
63.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Drug Development, DNA, Microfluidics, Genetics and genomics, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health
Business model
Manufacturing
Investment activity
1 company, latest Oct 2018
Capital deployed
—
Preferred round
ACQUISITION

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Jun 2021 $75M $300M IDG Capital · B Capital · Hong Kong Science & Technology Parks Corporation · Legend Star —
SERIES COther financing Aug 2019 $67M $268M IDG Capital · Sequoia ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

HiFiBiO Therapeutics website traffic

Latest recorded traffic for HiFiBiO Therapeutics is 2.5K monthly website visits, down 30.6% over the last three months. HiFiBiO Therapeutics's team declined 27.1% over the past year.

Latest monthly visits2.5K 3-month web change-30.6% 1-year team growth-27.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

HiFiBiO Therapeutics in the Cambridge ecosystem

Live from Dealroom

The HiFiBiO Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Nest.Bio Labs
  • Virtus Inspire Ventures
  • Sequoia
  • LYFE Capital
  • Legend Star
  • Proxima Ventures

Series B and later9 investors entered at this stage

  • IDG Capital
  • B Capital
  • Hong Kong Science & Technology Parks Corporation
  • Maison Capital
  • Grand Mount Capital
  • Trinity Innovation Fund
  • Hengxu Capital
  • Mirae Asset Capital
  • Sherpa Venture Partners

Other known investors4 additional known investors

  • CNRS Innovation
  • French National Centre for Scientific Research - CNRS
  • SATT Conectus
  • University of Strasbourg
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States48.6%
🇫🇷 France20%
🇨🇳 China20%
🇳🇱 Netherlands5.7%
🇩🇪 Germany2.9%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HiFiBiO Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HiFiBiO Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.